Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1152/ajprenal.00266.2016 http://scihub22266oqcxt.onion/10.1152/ajprenal.00266.2016 C5374308!5374308!27974318     free     free     free       Am+J+Physiol+Renal+Physiol 2017 ; 312 (3): F375-84 Nephropedia Template TP {{tp|p=27974318|t=2017. A perspective on chronic kidney disease progression |pdf=|usr=}}{{27974318}} gab.com Text A perspective on chronic kidney disease progression JO: Am J Physiol Renal Physiol http://www.kidney.de/pget.php?&tw=1&pmid=27974318 #FOAvip Chronic kidney disease (CKD) will progress to end stage without treatment, but the decline of renal function may not be linear. Compared with glomerular filtration rate and proteinuria, new surrogate markers, such as kidney injury molecule-1, neutrophil gelatinase-associated protein, apolipoprotein A-IV, and soluble urokinase receptor, may allow potential intervention and treatment in the earlier stages of CKD, which could be useful for clinical trials. New omic-based technologies reveal potential new genomic and epigenomic mechanisms that appear different from those causing the initial disease. Various clinical studies also suggest that acute kidney injury is a major risk for progressive CKD. To ameliorate the progression of CKD, the first step is optimizing renin-angiotensin-aldosterone system blockade. New drugs targeting endothelin, transforming growth factor-?, oxidative stress, and inflammatory- and cell-based regenerative therapy may have add-on benefit. Twit Text FOAVip A perspective on chronic kidney disease progression ????Am J Physiol Renal Physiol http://www.kidney.de/pget.php?&tw=1&pmid=27974318 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27974318 #FOAvip English Wikipedia <ref>{{Cite pmid|27974318}}</ref> A perspective on chronic kidney disease progression #MMPMID27974318 Zhong J; Yang HC; Fogo AB Am J Physiol Renal Physiol 2017[Mar]; 312 (3): F375-84 PMID27974318show ga Chronic kidney disease (CKD) will progress to end stage without treatment, but the decline of renal function may not be linear. Compared with glomerular filtration rate and proteinuria, new surrogate markers, such as kidney injury molecule-1, neutrophil gelatinase-associated protein, apolipoprotein A-IV, and soluble urokinase receptor, may allow potential intervention and treatment in the earlier stages of CKD, which could be useful for clinical trials. New omic-based technologies reveal potential new genomic and epigenomic mechanisms that appear different from those causing the initial disease. Various clinical studies also suggest that acute kidney injury is a major risk for progressive CKD. To ameliorate the progression of CKD, the first step is optimizing renin-angiotensin-aldosterone system blockade. New drugs targeting endothelin, transforming growth factor-?, oxidative stress, and inflammatory- and cell-based regenerative therapy may have add-on benefit. äA perspective on chronic kidney disease progression (epmc).pdf DeepDyve Pubget Overpricing